drug · small molecule

IGALMI

updated 2mo ago

by $BTAI BioXcel Therapeutics, Inc.🔗 ChEMBL

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 investigational indications.

targets

Adrenergic receptor alpha-2

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

IGALMI

trade names

Cepedex, Dexdomitor, Dexdor, Dexmedetomidine accord, Dexmedetomidine hydrochloride, Igalmi

generic

DEXMEDETOMIDINE HYDROCHLORIDE

MOA

12.1 Mechanism of Action Dexmedetomidine is an alpha-2 adrenergic receptor agonist. The mechanism of action of IGALMI in the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder is thought to be due to activation of presynaptic alpha-2 adrenergic receptors.

indication

1 INDICATIONS AND USAGE IGALMI is indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI is an alpha-2 adrenergic receptor agonist indicated in adults for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder. ( 1 ) Limitations of Use : The safety and effectiveness of IGALMI has not been established beyond 24 hours from the first dose. ( 1 , 5.4 , 5.5 ) Limitations of Use The safety and effectiveness of IGALMI have not been established beyond 24 hours from the first dose [see Warnings and Precautions (5.4 , 5.5) ] .

IGALMI

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)

🐶 often sniffed alongside

Trials studying IGALMI